Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
Neoadjuvant sintilimab combined with chemotherapy has promising efficacy and safety in the treatment of locally advanced resectable ESCC. The treatment modality has the potential to become a standard therapy for locally advanced resectable ESCC.
Authors
- Shifa Zhang (ORCID: https://orcid.org/0000-0002-7361-9336)
- Ru Song (ORCID: https://orcid.org/0000-0002-1324-777X)
- Hongfeng Liu (ORCID: https://orcid.org/0000-0003-3083-4527)
- Junhui Sun
- Lei Chen (ORCID: https://orcid.org/0000-0002-8257-5806)
- Hongmei Ma (ORCID: https://orcid.org/0000-0002-5028-8060)
- Junjun Huang (ORCID: https://orcid.org/0000-0001-6407-3530)
- Haibo Cai (ORCID: https://orcid.org/0000-0002-6312-5439)
- Dongbao Yang
- Kaize Zhong
Institutions
- Huzhou Central Hospital (CN)
- Jining First People's Hospital (CN)
- Jining Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3389/fimmu.2024.1453176
- Citations
- 6
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- Wu Jieping Medical Foundation